Loading...
•
Sep 30, 2023
Mimedx Q3 2023 Earnings Report
Mimedx reported net sales growth exceeding 20%, with an Adjusted EBITDA margin of 21.6% and a $12.5 million increase in cash balance.
Key Takeaways
MiMedx announced strong Q3 2023 results, with net sales increasing by 20.7% year-over-year to $81.7 million and GAAP net income of $8.5 million. The company's Adjusted EBITDA was $17.6 million, representing 21.6% of net sales. MIMEDX raised its full-year 2023 net sales percentage growth outlook to the high teens.
Net sales for Q3 2023 reached $81.7 million, a 20.7% increase compared to Q3 2022.
GAAP net income for Q3 2023 was $8.5 million.
Adjusted EBITDA for Q3 2023 was $17.6 million, representing 21.6% of net sales.
Launched EPIEFFECT™, the latest addition to MIMEDX’s portfolio of Advanced Wound Care products.
Forward Guidance
MIMEDX expects full year 2023 net sales percentage growth to be in the high teens.The Company continues to expect Adjusted EBITDA margin in the second half of 2023 to exceed 20%. The Company anticipates cash on the balance sheet at December 31, 2023 to be above $80 million.
Positive Outlook
- Continued demand for the Company’s Wound & Surgical product offering across its sites of service
- Ongoing uptake of new products launched in the last twelve months
- Expects Adjusted EBITDA margin in the second half of 2023 to exceed 20%
- Anticipates cash on the balance sheet at December 31, 2023 to be above $80 million.
- Strong commercial momentum in the business on a year-to-date basis
Challenges Ahead
- Future sales are uncertain and are affected by competition
- Future sales are affected by access to customers and patient access to healthcare providers
- Future sales are affected by the reimbursement environment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...